IMforte: Adding lurbinectedin to atezolizumab improves PFS and OS as first-line maintenance therapy in patients with ES-SCLC

ELCC 2025

Lung, Respiratory and Thoracic Cancer

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Lung, Respiratory and Thoracic Cancer

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy

Eur J Cancer

Monaca F, Gomez-Randulfe I, Parreira AS, Longo V, Galetta D, Pilotto S, Polidori S, Cantale O, Stefani A, Vita E, Taylor P, Gomes F, Cove-Smith L, Summers Y, Tortora G, Blackhall F, Novello S, Bria E, Califano R

doi: 10.1016/j.ejca.2025.115435

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Gynecologic Cancer

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Ann Oncol

Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I, PAOLA-1/ENGOT-ov25 investigators

doi: 10.1016/j.annonc.2024.10.828

CHICAGO 2025

Breast Cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

CHICAGO 2025

Lung, Respiratory and Thoracic Cancer

DeLLphi-304: Tarlatamab significantly improves OS versus chemotherapy in previously treated patients with SCLC

CHICAGO 2025

Gastrointestinal Cancer

BREAKWATER: Encorafenib plus cetuximab and mFOLFOX6 improves PFS and OS in treatment-naïve patients with BRAF V600E-mutant mCRC

Breast Cancer

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Eur J Cancer

Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T

doi: 10.1016/j.ejca.2025.115689

CHICAGO 2025

Gastrointestinal Cancer

Related content

MARIPOSA: First-line amivantamab plus lazertinib improves OS versus osimertinib in patients with EGFR-mutant advanced NSCLC

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

DeLLphi-304: Tarlatamab significantly improves OS versus chemotherapy in previously treated patients with SCLC

BREAKWATER: Encorafenib plus cetuximab and mFOLFOX6 improves PFS and OS in treatment-naïve patients with BRAF V600E-mutant mCRC

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA